139 related articles for article (PubMed ID: 34482696)
1. Microemulsion for Prolonged Release of Fenretinide in the Mammary Tissue and Prevention of Breast Cancer Development.
Salata GC; Malagó ID; Carvalho Dartora VFM; Marçal Pessoa AF; Fantini MCA; Costa SKP; Machado-Neto JA; Lopes LB
Mol Pharm; 2021 Sep; 18(9):3401-3417. PubMed ID: 34482696
[TBL] [Abstract][Full Text] [Related]
2. A Lipid-Based In Situ-Forming Hexagonal Phase for Prolonged Retention and Drug Release in the Breast Tissue.
Salata GC; Malagó ID; Lopes LB
AAPS PharmSciTech; 2022 Sep; 23(7):260. PubMed ID: 36123553
[TBL] [Abstract][Full Text] [Related]
3. 4-(hydroxyphenyl)retinamide selectively inhibits the development and progression of ductal hyperplastic lesions and carcinoma in situ in mammary gland.
Green A; Shilkaitis A; Christov K
Carcinogenesis; 1999 Aug; 20(8):1535-40. PubMed ID: 10426803
[TBL] [Abstract][Full Text] [Related]
4. Microencapsulation of amorphous solid dispersions of fenretinide enhances drug solubility and release from PLGA in vitro and in vivo.
Nieto K; Mallery SR; Schwendeman SP
Int J Pharm; 2020 Aug; 586():119475. PubMed ID: 32525080
[TBL] [Abstract][Full Text] [Related]
5. In vivo controlled release of fenretinide from long-acting release depots for chemoprevention of oral squamous cell carcinoma recurrence.
Nieto K; Pei P; Wang D; Mallery SR; Schwendeman SP
Int J Pharm; 2018 Mar; 538(1-2):48-56. PubMed ID: 29170116
[TBL] [Abstract][Full Text] [Related]
6. Effects of body weight gain reduction resulting from chemopreventive agent treatment on mammary gland morphology.
Rodríguez-Burford C; Steele VE; Anderson AS; Stockard CR; Weiss HL; Eto I; Johanning GL; Grizzle WE; Grubbs CJ
Nutr Cancer; 2002; 43(1):67-75. PubMed ID: 12467137
[TBL] [Abstract][Full Text] [Related]
7. Effect of early vs. late administration of 4-hydroxyphenylretinamide (4-HPR) on N-methyl-N-nitrosourea (MNU)-induced mammary tumorigenesis.
Crist KA; Wang Y; Lubet RA; Steele VE; Kelloff GJ; You M
J Cell Biochem Suppl; 1997; 27():92-9. PubMed ID: 9591198
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in rats.
Kisková T; Jendželovský R; Rentsen E; Maier-Salamon A; Kokošová N; Papčová Z; Mikeš J; Orendáš P; Bojková B; Kubatka P; Svoboda M; Kajo K; Fedoročko P; Jäger W; Ekmekcioglu C; Kassayová M; Thalhammer T
Eur J Cancer Prev; 2014 Nov; 23(6):506-13. PubMed ID: 25254309
[TBL] [Abstract][Full Text] [Related]
9. Hormonal prevention of breast cancer: mimicking the protective effect of pregnancy.
Guzman RC; Yang J; Rajkumar L; Thordarson G; Chen X; Nandi S
Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2520-5. PubMed ID: 10051675
[TBL] [Abstract][Full Text] [Related]
10. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
Costa A; Formelli F; Chiesa F; Decensi A; De Palo G; Veronesi U
Cancer Res; 1994 Apr; 54(7 Suppl):2032s-2037s. PubMed ID: 8137334
[TBL] [Abstract][Full Text] [Related]
11. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer.
Conley B; O'Shaughnessy J; Prindiville S; Lawrence J; Chow C; Jones E; Merino MJ; Kaiser-Kupfer MI; Caruso RC; Podgor M; Goldspiel B; Venzon D; Danforth D; Wu S; Noone M; Goldstein J; Cowan KH; Zujewski J
J Clin Oncol; 2000 Jan; 18(2):275-83. PubMed ID: 10637240
[TBL] [Abstract][Full Text] [Related]
12. Synthetic retinoid fenretinide in breast cancer chemoprevention.
Bonanni B; Lazzeroni M; Veronesi U
Expert Rev Anticancer Ther; 2007 Apr; 7(4):423-32. PubMed ID: 17428163
[TBL] [Abstract][Full Text] [Related]
13. Effect of reduced body weight gain on the evaluation of chemopreventive agents in the methylnitrosourea-induced mammary cancer model.
Rodríguez-Burford C; Lubet RA; Eto I; Juliana MM; Kelloff GJ; Grubbs CJ; Steele VE
Carcinogenesis; 1999 Jan; 20(1):71-6. PubMed ID: 9934852
[TBL] [Abstract][Full Text] [Related]
14. Safety of the synthetic retinoid fenretinide: long-term results from a controlled clinical trial for the prevention of contralateral breast cancer.
Camerini T; Mariani L; De Palo G; Marubini E; Di Mauro MG; Decensi A; Costa A; Veronesi U
J Clin Oncol; 2001 Mar; 19(6):1664-70. PubMed ID: 11250995
[TBL] [Abstract][Full Text] [Related]
15. Chemopreventive effect of a novel oleanane triterpenoid in a chemically induced rodent model of breast cancer.
Bishayee A; Mandal A; Thoppil RJ; Darvesh AS; Bhatia D
Int J Cancer; 2013 Sep; 133(5):1054-63. PubMed ID: 23404339
[TBL] [Abstract][Full Text] [Related]
16. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.
Decensi A; Robertson C; Guerrieri-Gonzaga A; Serrano D; Cazzaniga M; Mora S; Gulisano M; Johansson H; Galimberti V; Cassano E; Moroni SM; Formelli F; Lien EA; Pelosi G; Johnson KA; Bonanni B
J Clin Oncol; 2009 Aug; 27(23):3749-56. PubMed ID: 19597031
[TBL] [Abstract][Full Text] [Related]
17. Breast cancer and fenretinide, an analogue of vitamin A.
Cobleigh MA
Leukemia; 1994; 8 Suppl 3():S59-63. PubMed ID: 7808027
[TBL] [Abstract][Full Text] [Related]
18. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models.
Bhat KP; Lantvit D; Christov K; Mehta RG; Moon RC; Pezzuto JM
Cancer Res; 2001 Oct; 61(20):7456-63. PubMed ID: 11606380
[TBL] [Abstract][Full Text] [Related]
19. Effects of different durations of estrogen and progesterone treatment on development of N-methyl-N-nitrosourea-induced mammary carcinomas in female Lewis rats.
Yuri T; Tsukamoto R; Uehara N; Matsuoka Y; Tsubura A
In Vivo; 2006; 20(6B):829-36. PubMed ID: 17203775
[TBL] [Abstract][Full Text] [Related]
20. Rethinking Breast Cancer Chemoprevention: Technological Advantages and Enhanced Performance of a Nanoethosomal-Based Hydrogel for Topical Administration of Fenretinide.
Apolinário AC; Salata GC; de Souza MM; Chorilli M; Lopes LB
AAPS PharmSciTech; 2022 Apr; 23(4):104. PubMed ID: 35381947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
